Adagene Inc
NASDAQ:ADAG

Watchlist Manager
Adagene Inc Logo
Adagene Inc
NASDAQ:ADAG
Watchlist
Price: 2.1935 USD -2.94% Market Closed
Market Cap: 97.1m USD
Have any thoughts about
Adagene Inc?
Write Note

Adagene Inc
Other Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Adagene Inc
Other Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Items CAGR 3Y CAGR 5Y CAGR 10Y
Adagene Inc
NASDAQ:ADAG
Other Items
$7.7k
CAGR 3-Years
-90%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Other Items
ÂĄ4.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Other Items
-ÂĄ894.1m
CAGR 3-Years
N/A
CAGR 5-Years
-53%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Other Items
-ÂĄ729.4m
CAGR 3-Years
-23%
CAGR 5-Years
N/A
CAGR 10-Years
-63%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Other Items
ÂĄ173.9m
CAGR 3-Years
N/A
CAGR 5-Years
3%
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Other Items
-ÂĄ1.2B
CAGR 3-Years
-11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Adagene Inc
Glance View

Market Cap
97.1m USD
Industry
Biotechnology

Adagene, Inc. engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

ADAG Intrinsic Value
0.924 USD
Overvaluation 58%
Intrinsic Value
Price

See Also

What is Adagene Inc's Other Items?
Other Items
7.7k USD

Based on the financial report for Dec 31, 2023, Adagene Inc's Other Items amounts to 7.7k USD.

What is Adagene Inc's Other Items growth rate?
Other Items CAGR 3Y
-90%

The average annual Other Items growth rates for Adagene Inc have been -90% over the past three years .

Back to Top